Content area
Full text
TIMMY GARDE, LEVLANE'S chief innovation leader, life sciences, says he tensed up when the call came through from Agile Therapeutics. While he thought the agency's pitch for an AOR assignment from Agile had gone well, he knew it was competing against much larger agencies - some of them, he adds, publicly held.
Looking out over downtown Philadelphia, he picked up the phone. "'You just blew us away with your structure and your thinking,'" he recalls the Agile exec saying.
"That was a breakthrough and a revelation. They liked our partnership model. They liked that our resources go outside traditional pharma thinking and that we can use our insights in areas such as banks and retail to help them with a major product launch."
LevLane enjoyed other successes on the client front, which spurred a small bump in revenue to $8.9 million in 2016, up 3.5% from 2015.
Besides the Agile win...